University of Minnesota, MN, USA.
Blood. 2013 Feb 21;121(8):1245-6. doi: 10.1182/blood-2013-01-472563.
Studies by Amabile et al reported in this issue of Blood use a novel strategy of teratoma formation from human induced pluripotent stem cells (iPSCs) to isolate hematopoietic stem/progenitor cells (HSPCs) capable of in vivo engraftment and producing functional lymphocytes.(1)
阿玛比尔等人在本期《血液》中报道的研究使用了一种从人诱导多能干细胞（iPSC）中形成畸胎瘤的新策略，以分离能够体内植入和产生功能性淋巴细胞的造血干/祖细胞（HSPC）。
